Compass Pathways
在场
Compass Pathways 是一家在股票代码 CMPS (GB) 下上市的公司。
高管
查看带有其 29 名主要高管的组织结构图
Compass Pathways 搜索最多的简介
高管在Compass Pathways变化
- Gino Santini已作为Chairman of the Board加入公司 (新闻发布的2024八月2号).
- Lori EnglebertLori Englebert 将于20247月8作为 Chief Commercial Officer 加入公司 (新闻发布的2024六月27号).
- David Norton 曾任 Lead Director, 现升职为 Interim Chairman of the Board (新闻发布的2024三月30号).
创建提醒
跟踪 Compass Pathways 的高管变动
生物技术
Compass Pathways 拥有 2,332 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- March Biosciences 刚刚宣布为 28 筹款数百万美元。 (公布2024十二月3号).
- Lyell Immunopharma 已收购 ImmPACT Bio (公布2024十一月29号).
- Hopo Therapeutics 刚刚宣布为 226 筹款数百万美元。 (公布2024十一月29号).
生物技术 行业的其他推荐联系人
消息
Compass Pathways 的最新新闻稿
- Compass Pathways - News & events - News
- Compass Pathways - News & events - Events & presentations
- Mental Health Care News, Articles & Stories from Compass Pathways
- Study results of psilocybin treatment in bipolar II depression published in JAMA Psychiatry | Compass Pathways
- Compass Pathways initiates UK component of global phase 3 study of psilocybin treatment in treatment-resistant depression, and launches new research center | Compass Pathways
- Mental Health Care News, Articles & Stories from Compass Pathways
- Mental Health Care News, Articles & Stories from Compass Pathways
- COMPASS Pathways announces publication of first study evaluating potential of AI model to predict outcomes of COMP360 psilocybin treatment in treatment-resistant depression | COMPASS Pathways
- COMP360 psilocybin treatment in TRD with antidepressants | COMPASS Pathways
- COMPASS Pathways announces publication of positive data from treatment-resistant depression phase 2 clinical trial of COMP360 psilocybin alongside antidepressants in Nature journal, Neuropsychopharmacology | COMPASS Pathways
- View more press releases Close
关于 Compass Pathways 的社交媒体
保持联系
通过电子邮件联系联系该企业高管，包括 Kabir Nath 
